Table 1 Baseline demographic and clinical characteristics by arm
Immediate switch arm N = 33 | Delayed switch arm N = 39 | ||
|---|---|---|---|
Age, mean years (SD) | 53 (8) | 56 (7) | |
Self-reported male sex, n (%) | 29 (88.0) | 35 (90.0) | |
White race, n (%) | 23 (69.7) | 30 (76.9) | |
CD4 T count, median cells/mm3 (IQR)a | 560 (457–800)a | 632 (453–854) | |
ART duration, median years (IQR) | 30; 17.1 (8.7–21.3)b | 39; 17.6 (10.9–23.8) | |
bPI at randomisation, n (%) | Darunavir | 28 (84.8) | 30 (76.9) |
Atazanavir | 5 (15.2) | 9 (23.1) | |
NRTI backbone, n (%) | TDF-based | 17 (51.5) | 20 (51.3) |
TAF-based | 6 (18.2) | 7 (17.9) | |
Non TDF/TAF-based | 4 (12.1) | 8 (20.5) | |
3TC or FTC | 22 (66.7) | 31 (79.5) | |
On lipid lowering drugs, n (%) | 11 (33.3) | 14 (35.9) | |
NRTI RAMs in historical genotypec, n (%) | |||
M184V/I alone | 12 (36.4) | 9 (23.1) | |
1 TAM | 6 (18.2) | 10 (25.6) | |
1 TAM + M184V/I | 4 (12.1) | 7 (18.0) | |
2 TAMs | 1 (3.0) | 3 (7.7) | |
2 TAMs + M184V/I | 2 (6.1) | 5 (12.8) | |
1 NAM + M184V/I | 3 (9.1) | 2 (5.1) | |
1 TAM + M184V/I + 1 NAM | 1 (3.0) | 2 (5.1) | |
2 TAMs + M184V/I + 1 NAM | 3 (9.1) | 1 (2.6) | |
1 TAM + 1 NAM | 1 (3.0) | 0 (0.0) | |
NRTI RAMs in baseline genotyped | |||
Any | 13 (39.4) | 20 (51.3) | |
None | 19 (57.6) | 16 (41.0) | |
Not available | 1 (3.0) | 3 (7.7) | |